AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (97.3%). Net sales break down by treatment area between oncology (41.9%), cardiovascular, renal and metabolic diseases (27.4%), respiratory and autoimmune diseases (20.7%), and other (10%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (2.7%).
Net sales are distributed geographically as follows: the United Kingdom (6.5%), Continental Europe (18.2%), Americas (38.7%) and Africa/Asia/Australia (36.6%).
Number of employees : 76 100 people.
2019 2020 Delta GBP (in Million) % GBP (in Million) % Oncology 6,794 35.5% 8,461 39.3% +24.54% Cardiovascular, Renal & Metabolism 5,413 28.3% 5,534 25.7% +2.22% Respiratory 4,226 22.1% 4,177 19.4% -1.14% Other Diseases 2,039 10.7% 2,017 9.4% -1.05% Externalisation Revenue 641.98 3.4% 566.93 2.6% -11.69%
2020 GBP (in Million) % United States 6,983 32.5% China 4,168 19.4% Japan 2,002 9.3% United Kingdom 1,358 6.3% Other Asia, Africa and Australasia 1,196 5.6% Other Continental Europe 1,085 5% Sweden 800.09 3.7% Germany 730.69 3.4% Other Americas 593.44 2.8% France 509.22 2.4%
Vote Quantity Free-Float Company-owned shares Total Float
Stock A
1
1,312,762,006
1,256,906,517
95.7% 0
0.0% 95.7%
Shareholders AstraZeneca PLC (GB0009895292) AstraZeneca PLC (US)
Name Equities % Wellington Management Co. LLP 68,525,329
5.22% Capital Research & Management Co. (World Investors) 56,102,804
4.27% BlackRock Investment Management (UK) Ltd. 54,582,684
4.16% Investor AB (Investment Company) 51,587,810
3.93% The Vanguard Group, Inc. 35,137,408
2.68% Norges Bank Investment Management 30,410,000
2.32% BlackRock Fund Advisors 24,843,394
1.89% BlackRock Advisors (UK) Ltd. 17,081,041
1.30% SSgA Funds Management, Inc. 13,640,628
1.04% Clearstream Banking SA 12,010,000
0.91%
Name Equities % Investor AB (Investment Company) 190,171,620
7.24% PRIMECAP Management Co. 49,913,226
1.90% Wellington Management Co. LLP 48,587,986
1.85% Capital Research & Management Co. (International Investors) 30,113,378
1.15% T. Rowe Price Associates, Inc. (Investment Management) 18,596,691
0.71% Fisher Asset Management LLC 18,388,688
0.70% GQG Partners LLC 15,411,453
0.59% Capital Research & Management Co. 14,965,800
0.57% Optiver US LLC 12,464,078
0.47% Regents of the University of California 10,965,024
0.42%
Name Equities % Valuation
AstraZeneca Pharma India Limited (506820) 18,750,000 75.0% 988,626,000 USD ADC Therapeutics SA (ADCT) 4,011,215 5.23% 98,435,216 USD Silence Therapeutics plc (SLN) 4,397,247 4.92% 37,685,990 USD Circassia Group Plc (CIR) 71,081,217 17.0% 34,396,201 USD Innate Pharma (IPH) 7,485,500 9.48% 32,079,335 USD PhaseBio Pharmaceuticals, Inc. (PHAS) 3,004,554 6.28% 9,103,799 USD Pieris Pharmaceuticals, Inc. (PIRS) 3,584,230 6.00% 7,741,937 USD Entasis Therapeutics Holdings Inc. (ETTX) 2,164,855 5.80% 4,535,371 USD
-
- Main Market
- OMX Stockholm 30 / FTSE 100, FTSE 350, FTSE All-Share, FTSE Eurotop 100, Low Carbon 100 Europe, NASDAQ OMX Nordic 120, OMX Nordic 40, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200, Stoxx UK 50
- Bloomberg Code :
AZN:LN
- Reuters Code :
AZN.L
- Datastream Code :
AZN
Company contact information
AstraZeneca runs into 'meaningful' investor revolt over pay
Sector Other Pharmaceuticals
Connections : AstraZeneca PLC
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
